Abstract
Purpose The effectiveness of traditional amblyopia therapies is largely restricted to childhood. However, recovery in adulthood is possible following removal or vision-limiting disease of the fellow eye. Study of this phenomenon is currently limited to isolated case reports and a few case series, with reported incidence ranging from 19-77% 1–5. We set out to accomplish two distinct goals: (1) define the incidence of clinically meaningful recovery and (2) elucidate the clinical features associated with greater amblyopic eye gains.
Methods A systematic review of 3 literature databases yielded 23 reports containing 109 cases of patients ≥18 years old with unilateral amblyopia and vision-limiting fellow eye pathology.
Results Study 1 revealed 25/42 (59.5%) of adult patients gained ≥2 logMAR lines in the amblyopia eye after FE vision loss. The overall degree of improvement is clinically meaningful (median 2.6 logMAR lines). Study 2 showed that for cases with amblyopic eye visual acuity improvement, recovery occurs within 12 months of initial loss of fellow eye vision. Regression analysis revealed that younger age, worse baseline acuity in the amblyopic eye, and worse vision in the fellow eye independently conferred greater gains in amblyopic eye visual acuity. Recovery occurs across amblyopia types and fellow eye pathologies, although disease entities affecting fellow eye retinal ganglion cells demonstrate shorter latencies to recovery.
Conclusions Amblyopia recovery after fellow eye injury demonstrates that the adult brain harbors the neuroplastic capacity for clinically meaningful recovery, which could potentially be harnessed by novel approaches to treat adults with amblyopia.
Competing Interest Statement
MFB: Luminopia, Inc. (scientific advisor, equity) EDG: Luminopia, Inc. (scientific advisor, equity, patent), Stoke Therapeutics Inc. (consultant) All other authors: none
Funding Statement
MPL: NIH F31 EY033996 MFB: NIH R01 EY029245, RPB42894, Picower Neurological Disorder Research Fund EDG: NIH K08 EY030164, Children's Hospital Ophthalmology Foundation
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
PubMed (1946-), Embase (1947-), and Web of Sciences Core Collection (1900-) databases
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Funding: MPL: NIH F31 EY033996
MFB: NIH R01 EY029245, RPB #42894, Picower Neurological Disorder Research Fund
EDG: NIH K08 EY030164, Children’s Hospital Ophthalmology Foundation
Conflict of interest statement: MFB: Luminopia, Inc. (scientific advisor, equity)
EDG: Luminopia, Inc. (scientific advisor, equity, patent), Stoke Therapeutics Inc. (consultant)
Data Availability
All data produced in the present work are contained in the manuscript
